Theralase Investment Opportunity Aug 2013

589 views

Published on

1. Production, marketing and distribution of the TLC-1000 and TLC-2000 Theralase Superpulsed Laser Technology for sale to healthcare practitioners nationally and internationally, interested in the safe and effective treatment of neuromuscular skeletal conditions through the elimination of pain and inflammation and the accelerated regeneration of tissue.
2. Commercialization of the patented TLC-3000 Laser and Photo Dynamic Compound Technology platform through preclinical research, FDA clinical trials and new technology development in the direct destruction of cancers for oncological applications and in the destruction of bacteria for sterilization of medical and food processing facilities.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
589
On SlideShare
0
From Embeds
0
Number of Embeds
15
Actions
Shares
0
Downloads
6
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Theralase Investment Opportunity Aug 2013

  1. 1. HEALING AT THE SPEED OF LIGHT August 1,2013 $0.25 $0.30 $0.145 7,531 CURRENT 52 WEEK HIGH 52 WEEK LOW AVG. VOLUME Investment Opportunity: Participation in a $3 M Private Placement Theralase Technologies Inc. (TSXV: TLT) Theralase Technologies Inc. is focused on a two‐part strategy: 1. Production, marketing and distribution of the FDA approved and proprietary Theralase Superpulsed Laser technology for sale to health care practitioners that are dedicated to the treatment of chronic pain, inflammatory conditions, sports injuries and wounds. In 1Q 2014, Theralase plans to launch the patented TLC‐2000 biofeedback laser system in Canada and USA to provide a quantum leap forward in therapeutic laser technology and to introduce the first recurring revenue model in a therapeutic laser. 2. Commercialization of patented cancer technology through preclinical research, human clinical trials and regulatory approvals in the direct destruction of cancer utilizing Theralase’s advanced new class of light activated Photo Dynamic Compounds (PDC) Therapeutic Laser Technology (TLT) Division Opportunity: • Launch a patented, next generation therapeutic laser system in Canada and the US in 1Q 2014 • Theralase will employ a recurring revenue model; whereby, the company will provide the technology, training, certification, service and customer referrals, in exchange for an initial upfront fee and monthly treatment fee based upon usage Upside: • $21 M a year therapeutic laser recurring revenue model in 3 years with 50% net margin • FDA approved, non-invasive, treatment of chronic pain and inflammation • World market exceeds $100 billion annually • Proven effective in blinded, randomised, controlled clinical studies • Incorporates TENS (Transcutaneous Electrical Nerve Stimulation) to allow additional CPT billing codes for the US market • Cumulative ROI: 1.5 Year: 200%, 2.5 Years: 300%, 3.5 Years: 700% Intellectual Property Therapeutic Laser Patents: USA Patent: 6,413,267, Canadian Patent: 2,315,521, Belgium, Italy, Great Britain, Germany, France, Spain Patent: 1075854 Why Invest? • International Patented Technology • Large Market Opportunity For more information, please contact Mr. Roger White, President and CEO, 1-866-843-5273, x:225 rwhite@theralase.com This executive summary contains forward-looking statements, which reflect the Company's current expectations regarding future events.The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Company • Designs, develops and manufactures patented, superpulsed laser technology • > 90% efficacy on a wide range of neural muscular skeletal conditions (i.e.: Low Back Pain, Knee Osteoarthritis, Shoulder Tendonitis) • Solid business built in Canada over the last 20 years consistently producing annual revenues of approximately $2 million with a flat bottom line. • Investments into next generation therapeutic laser technology and next generation cancer therapy have led to a loss of approximately $1.0 to $1.5 M annually. • 80% of sales completed in Ontario. Opportunity: Expansion of sales and marketing into Western Canada, the 5 largest states in the US (30% of US GDP and population) and other international markets with Theralase Laser Centres covering overhead. Strategy: • Launch Theralase Laser Centre / Sales and Marketing Office in Toronto, Ontario – May 2013 (Complete) • Launch Theralase Laser Centre / Sales and Marketing Office in Calgary, Alberta – September 2013 • Launch Theralase Laser Centre / Sales and Marketing Office in Manhattan, New York – March 2014 • Launch Theralase Laser Centre / Sales and Marketing Office in Los Angeles, California – March 2014 • Launch Theralase Laser Centre / Sales and Marketing Office in Tampa, Florida – June 2014 • Launch Theralase Laser Centre / Sales and Marketing Office in Houston, Texas – June 2014 • Launch Theralase Laser Centre / Sales and Marketing Office in Chicago, Illinois – September 2014 TSXV:TLT • Experienced Management Team and Advisors to Execute Strategy • Attractive ROI

×